Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib

European Journal of Radiology Open(2020)10.1016/j.ejro.2019.12.004Source: DataRank Database

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib is a research paper published in European Journal of Radiology Open (2020). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 0.44)OA: goldTopics (19)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Tomoyuki Hida ORCID,Sasha Kravets ORCID,Suzanne E. Dahlberg ORCID,Christine Lydon,Hiroto Hatabu ORCID

Live enrichment

PubMed:33102632 PMC:PMC7569410 OpenAlex:https://openalex.org/W3003595552

NCI NIH HHS

Grant: R01 CA203636

National Institutes of Health

Grant: R01CA203636 (NCI)

National Institutes of Health

Grant: 5R01CA203636-03

Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment

International Association for the Study of Lung Cancer

Post Marketing Royalties for EGFR Mutation testing

Roche

Konica-Minolta

Merck

AstraZeneca

Canon Inc.

Canon Medical Systems

Canon Medical Systems and Novartis

Conquer Cancer Foundation of the American Society of Clinical Oncology

Dana-Farber Cancer Institute

FWCI

0.44

Citation Percentile

0.6%

Citation Trend

2021

2023

2025

goldLicense: cc-by-nc-nd

journalhttp://www.ejropen.com/article/S2352047719300516/pdf

publisherhttp://www.ejropen.com/article/S2352047719300516/pdf

journalhttps://doi.org/10.1016/j.ejro.2019.12.004

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33102632

repositoryhttps://doaj.org/article/fa7c054ac3294121a62d3564f062b35b

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies03 medical and health sciences0302 clinical medicine

Keywords

CrizotinibMedicineLung cancerCancer researchOncologyALK inhibitorInternal medicineNon-small CellAlk RearrangementTumor Growth RatePrecision TherapyMedical physics. Medical radiology. Nuclear medicineR895-920Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib

FAIR Checklist

Authors (8)

Funding (14 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)